Top Research Reports for Eli Lilly, PepsiCo & Morgan Stanley

Zacks11-20 05:18

Tuesday, November 19, 2024 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484156907?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_9OKqED6rOANF8VtUei37A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea","is_english":true,"pubTime":"2024-11-20 05:18","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2484156907","market":"us","top_or_hot":-1,"title":"Top Research Reports for Eli Lilly, PepsiCo & Morgan Stanley","media":"Zacks","content":"<div>\n<p>Tuesday, November 19, 2024\nThe Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly ...</p>\n\n<a href=\"https://finance.yahoo.com/news/top-research-reports-eli-lilly-211800630.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Research Reports for Eli Lilly, PepsiCo & Morgan Stanley</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Research Reports for Eli Lilly, PepsiCo & Morgan Stanley\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-20 05:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/top-research-reports-eli-lilly-211800630.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tuesday, November 19, 2024\nThe Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly ...</p>\n\n<a href=\"https://finance.yahoo.com/news/top-research-reports-eli-lilly-211800630.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":"https://finance.yahoo.com/news/top-research-reports-eli-lilly-211800630.html","article_id":"2484156907","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_9OKqED6rOANF8VtUei37A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484156907","pubTimestamp":1732051080,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"However, declining sales of Trulicity, rising pricing pressure on some drugs and potential competition in the GLP-1 diabetes/obesity market are some top-line headwinds.PepsiCo’s shares have underperformed the Zacks Beverages – Soft drinks industry over the past year . The Zacks analyst believes that largely due to challenges in its North American operations since the start of 2024 that includes reduced consumer demand and product recalls in the QFNA segment, the company has underperformed over the past year. Additionally, adverse currency rates continue to pose challenges.Yet, it is well-poised to benefit from strength and resilience in core categories, diversified portfolio, modernized supply chain, improved digital capabilities and flexible go-to-market distribution systems. The company's international business continues to hallmark its overall performance.Other noteworthy reports we are featuring today include Alibaba Group Holding Ltd. , The Walt Disney Co.  and Trane Technologies ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"LLY":"礼来","PEP":"百事可乐","TT":"Trane技术","MS":"摩根士丹利","DIS":"迪士尼","CI":"信诺保险","HBBD.SI":"Alibaba HK SDR 5to1","BABA":"阿里巴巴"},"translate_title":"礼来公司、百事可乐和摩根士丹利的热门研究报告","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1,"MS":1,"PEP":1,"BABA":0.9,"CI":0.9,"DIS":0.9,"HBBD.SI":0.9,"TT":0.9},"content_text":"Tuesday, November 19, 2024\nThe Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), PepsiCo, Inc. (PEP) and Morgan Stanley (MS). These research reports have been hand-picked from roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>\nEli Lilly’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the last two years (+101.3% vs. +16.6%). The Zacks analyst believes that the company has seen unparalleled success with its GLP-1 drugs, Mounjaro and Zepbound. In the past couple of years, Lilly has received approvals for several new drugs and witnessed pipeline and regulatory success.\nHowever, declining sales of Trulicity, rising pricing pressure on some drugs and potential competition in the GLP-1 diabetes/obesity market are some top-line headwinds.\n(You can read the full research report on Eli Lilly here >>>)\nPepsiCo’s shares have underperformed the Zacks Beverages – Soft drinks industry over the past year (-4.9% vs. +4.0%). The Zacks analyst believes that largely due to challenges in its North American operations since the start of 2024 that includes reduced consumer demand and product recalls in the QFNA segment, the company has underperformed over the past year. Additionally, adverse currency rates continue to pose challenges.\nYet, it is well-poised to benefit from strength and resilience in core categories, diversified portfolio, modernized supply chain, improved digital capabilities and flexible go-to-market distribution systems. The company's international business continues to hallmark its overall performance.\n(You can read the full research report on PepsiCo here >>>)\nShares of Morgan Stanley have outperformed the Zacks Financial - Investment Bank industry over the last six months (+33.4% vs. +22.8%). Per the Zacks analyst, a gradual revival in the investment banking (IB) business and a solid IB pipeline are expected to support its financials. Efforts to become less dependent on capital-markets-driven revenues, inorganic expansion/strategic alliance and high rates will also aid the top line.\nHowever, operating expenses are likely to stay elevated amid business expansion efforts. The ambiguity of the performance of the capital markets is a concern and might hurt the Institutional Securities segment’s prospects.\n(You can read the full research report on Morgan Stanley here >>>)\nOther noteworthy reports we are featuring today include Alibaba Group Holding Ltd. (BABA), The Walt Disney Co. (DIS) and Trane Technologies plc (TT).Mark VickerySenior EditorNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>\nToday's Must Read\nLilly's (LLY) Mounjaro, Zepbound Q4 Sales Soft, Demand Solid\nPepsiCo's (PEP) Investments in Business Drive the Top Line\nRates, IB Business Aid Morgan Stanley (MS), High Costs a Woe\nFeatured Reports\nDisney (DIS) Banks on Disney+, Theme Parks Business GrowthPer the Zacks analyst, growing popularity of Disney+ makes it a key catalyst for Disney's growth prospects. Moreover, strength in domestic theme parks is expected to drive top-line growth.\nCigna (CI) Gains from Solid Evernorth Unit, High Costs HurtPer the Zacks analyst, Cigna gains from significant client wins in Evernorth Health Services and premium rate hikes and business mix in Cigna Healthcare. However, rising costs are a concern.\nCapex Aids CenterPoint Energy (CNP), Supply Chain Issue WoesPer the Zacks analyst, CenterPoint Energy makes substantial capital investments to enhance the reliability of its electric utility systems. Yet supply chain issues pose a risk to its growth.\nMacau Growth and BetMGM Boost MGM Resorts' (MGM) ProspectsPer the Zacks analyst, MGM Resorts is likely to benefit from strong Macau performance, digital expansion through BetMGM and strategic partnerships. Also, focus on international expansion bode well.\nMarathon (MRO) to Gain from ConocoPhillips DealThe Zacks analyst believes that Marathon Oil's proposed acquisition by ConocoPhillips will lead to significant synergies and help it become part of a larger, financially robust entity.\nU.S. Cellular (USM) Rides on Healthy Demand, Cost DisciplinePer the Zacks analyst, solid traction in the fixed wireless portfolio and tower rental business will likely boost U.S. Cellular's top line. The cost optimization initiative is a positive.\nStrong Demand Offsets West Pharmaceuticals' (WST) FX HeadwindPer the Zacks analyst, continued strength in West Pharmaceuticals' proprietary products segment will drive prospects amid uncertainty in global economy. FX headwind to hurt 2024 revenues by $5 million\nNew Upgrades\nStrong Commercial HVAC Markets Aid Trane Technologies (TT)Per the Zacks analyst, Trane Technologies' top-line benefits from strong Commercial HVAC Markets. Energy-efficient product installation and decarbonizing the built environment strengthens the market.\nAlibaba (BABA) Gains From International Commerce BusinessesPer the Zacks analyst, strength across AliExpress' Choice and cross-border-related value-added services is benefiting Alibaba's international commerce retail and wholesale businesses.\nStrategic Plan, Solid Balance Sheet Aid Texas Capital (TCBI)Per the Zacks analyst, Texas Capital's strategic plan to expand its product offerings and digitalize operations will likely boost financials. Solid balance sheet is an added advantage.\nNew Downgrades\nStop-Sale Orders, Hurricane Effect to Mar Asbury (ABG) ProfitsOngoing stop-sale orders for Toyota, Lexus, Honda and BMW models, coupled with the fallout from Hurricane Milton, are set to limit Asbury's Q4 profits, making the Zacks analyst bearish on the stock. \nRising Costs Will Trim Acadia Healthcare's (ACHC) MarginsPer the Zacks analyst, increasing salaries, wages and benefits will keep pushing Acadia Healthcare's expenses higher, eroding its profits. Also, volumes will likely take a hit from media scrutiny.\nLow Demand for Destination Mountain Hurt Vail Resorts (MTN)Per the Zacks analyst, Vail Resorts is hurting from lower demand for destination mountain travel and weather-related operational disruptions. Also, ongoing inflationary risks add to the downtrend.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nMorgan Stanley (MS) : Free Stock Analysis Report\nEli Lilly and Company (LLY) : Free Stock Analysis Report\nPepsiCo, Inc. (PEP) : Free Stock Analysis Report\nThe Walt Disney Company (DIS) : Free Stock Analysis Report\nTrane Technologies plc (TT) : Free Stock Analysis Report\nAlibaba Group Holding Limited (BABA) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484156907"}